Related Experiment Video
Updated: Jun 14, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer
Meng Liu1, Anna-Karin M Sjogren, Christin Karlsson
1Wallenberg Laboratory, Institute of Medicine, Sahlgrenska University Hospital, S-41345 Gothenburg, Sweden.
Abstract:
RAS and RHO proteins, which contribute to tumorigenesis and metastasis, undergo posttranslational modification with an isoprenyl lipid by protein farnesyltransferase (FTase) or protein geranylgeranyltransferase-I (GGTase-I). Inhibitors of FTase and GGTase-I were developed to block RAS-induced malignancies, but their utility has been difficult to evaluate because of off-target effects, drug resistance, and toxicity. Moreover, the impact of FTase deficiency and combined FTase/GGTase-I deficiency has not been evaluated with genetic approaches. We found that inactivation of FTase eliminated farnesylation of HDJ2 and H-RAS, prevented H-RAS targeting to the plasma membrane, and blocked proliferation of primary and K-RAS(G12D)-expressing fibroblasts. FTase inactivation in mice with K-RAS-induced lung cancer reduced tumor growth and improved survival, similar to results obtained previously with inactivation of GGTase-I. Simultaneous inactivation of FTase and GGTase-I markedly reduced lung tumors and improved survival without apparent pulmonary toxicity. These data shed light on the biochemical and therapeutic importance of FTase and suggest that simultaneous inhibition of FTase and GGTase-I could be useful in cancer therapeutics.
Insights
Inactivating protein farnesyltransferase (FTase) and protein geranylgeranyltransferase-I (GGTase-I) genetically reduced lung tumors. Simultaneous genetic inhibition of FTase and GGTase-I shows promise for cancer therapeutics.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- RAS and RHO proteins are crucial in tumorigenesis and metastasis.
- Posttranslational modification by FTase or GGTase-I affects these proteins.
- Previous attempts to inhibit FTase/GGTase-I faced challenges like off-target effects and toxicity.
Purpose of the Study:
- To evaluate the impact of FTase deficiency and combined FTase/GGTase-I deficiency using genetic approaches.
- To explore the therapeutic potential of simultaneous FTase and GGTase-I inhibition in cancer.
Main Methods:
- Genetic inactivation of FTase in cell cultures and mouse models.
- Assessment of protein farnesylation, protein localization, and cell proliferation.
- Evaluation of tumor growth and survival in K-RAS-induced lung cancer models.
- Combined genetic inactivation of FTase and GGTase-I.
Main Results:
- FTase inactivation prevented H-RAS farnesylation and plasma membrane targeting, inhibiting fibroblast proliferation.
- FTase inactivation in mice reduced lung tumor growth and improved survival.
- Simultaneous inactivation of FTase and GGTase-I significantly reduced lung tumors and improved survival with no apparent pulmonary toxicity.
Conclusions:
- FTase plays a significant biochemical and therapeutic role in cancer.
- Simultaneous genetic inhibition of FTase and GGTase-I is a promising strategy for cancer therapeutics.
- This approach may overcome limitations of previous inhibitor-based strategies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
In-vitro Mutagenesis

